candesartan has been researched along with Cirrhoses, Experimental Liver in 4 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Candesartan was administered orally for 21 days immediately after bile duct ligation to evaluate its preventive effect, and for 21 days starting 3 weeks after bile duct ligation to evaluate its therapeutic effect." | 1.33 | Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats. ( Koda, M; Matsunaga, Y; Murawaki, Y; Ueki, M; Yamamoto, S, 2006) |
| "Candesartan cilexetil treatment significantly reduced the fibrosis development." | 1.32 | Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis. ( Bayram, I; Ozbek, H; Tuncer, I; Ugras, S, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tuncer, I | 1 |
| Ozbek, H | 1 |
| Ugras, S | 1 |
| Bayram, I | 1 |
| Yoshiji, H | 2 |
| Kuriyama, S | 2 |
| Noguchi, R | 2 |
| Yoshii, J | 2 |
| Ikenaka, Y | 2 |
| Yanase, K | 1 |
| Namisaki, T | 1 |
| Kitade, M | 1 |
| Yamazaki, M | 1 |
| Tsujinoue, H | 2 |
| Fukui, H | 2 |
| Ueki, M | 1 |
| Koda, M | 1 |
| Yamamoto, S | 1 |
| Matsunaga, Y | 1 |
| Murawaki, Y | 1 |
| Nakatani, T | 1 |
4 other studies available for candesartan and Cirrhoses, Experimental Liver
| Article | Year |
|---|---|
Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2003 |
Combination of interferon-beta and angiotensin-converting enzyme inhibitor, perindopril, attenuates the murine liver fibrosis development.
Topics: Actins; Angiotensin-Converting Enzyme Inhibitors; Animals; Antiviral Agents; Benzimidazoles; Biomark | 2005 |
Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cells, Culture | 2006 |
Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats.
Topics: Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Endothelial Growth Factors; Immunohisto | 2001 |